EICHOR
● Completed
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer (NSCLC) · Sponsor: Hoffmann-La Roche
About this study
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (189)
| Stanford University | Palo Alto, California, United States | — |
| Banner MD Anderson Cancer Center | Greeley, Colorado, United States | — |
| Florida Cancer Specialists | Fort Myers, Florida, United States | — |
| Cancer Care Centers of Brevard | Palm Bay, Florida, United States | — |
| Woodlands Medical Specialists, P.A. | Pensacola, Florida, United States | — |
| Florida Cancer Specialist, North Region | St. Petersburg, Florida, United States | — |
| Northwest Georgia Oncology Centers PC - Marietta | Marietta, Georgia, United States | — |
| Illinois Cancer Care | Peoria, Illinois, United States | — |
| New England Cancer Specialists | Brunswick, Maine, United States | — |
| Southcoast Health System | Fairhaven, Massachusetts, United States | — |
| Minnesota Oncology Hematology | Minneapolis, Minnesota, United States | — |
| HCA Midwest Health | Kansas City, Missouri, United States | — |
+ 177 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04513925